pentoxifylline has been researched along with Alcoholic Hepatitis in 85 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alcoholic hepatitis (AH) markedly decreases the urea synthesis capacity." | 9.27 | Time course of compromised urea synthesis in patients with alcoholic hepatitis. ( Aagaard, NK; Glavind, E; Gronbaek, H; Orntoft, NW; Thomsen, KL; Vilstrup, H, 2018) |
| "Patients with SAH given prednisolone are at greater risk for developing serious infections and infections after treatment than patients not given prednisolone, which may offset its therapeutic benefit." | 9.24 | In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. ( Allison, M; Atkinson, SR; Austin, A; Forrest, EH; Gleeson, D; Knapp, S; Masson, S; Maurice, J; McCune, A; Patch, D; Richardson, P; Ryder, SD; Thursz, MR; Vergis, N; Wright, M, 2017) |
| "The aim of the clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis trial was to resolve the clinical dilemma on the use of prednisolone or PTX." | 9.20 | The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial. ( Allison, M; Austin, A; Bowers, M; Day, C; Downs, N; Forrest, E; Gleeson, D; Homer, T; Kirkman, S; Masson, S; McCune, A; Mellor, J; O'Grady, J; Patch, D; Ratcliffe, I; Richardson, P; Roderick, P; Ryder, S; Stanton, L; Ternent, L; Thursz, M; Vale, L; Wright, M, 2015) |
| "Pentoxifylline did not improve survival in patients with alcoholic hepatitis." | 9.20 | Prednisolone or pentoxifylline for alcoholic hepatitis. ( Allison, M; Austin, A; Bowers, M; Day, CP; Downs, N; Forrest, EH; Gleeson, D; Grant, A; Hood, S; MacGilchrist, A; Masson, S; McCune, A; Mellor, J; O'Grady, J; Patch, D; Ratcliffe, I; Richardson, P; Roderick, P; Ryder, S; Stanton, L; Thursz, MR; Vergis, N; Wright, M, 2015) |
| "To evaluate the impact of metadoxine (MTD) on the 3- and 6-mo survival of patients with severe alcoholic hepatitis (AH)." | 9.20 | Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. ( Abdo-Francis, JM; Cruz-Herrera, J; Higuera-de la Tijera, F; Pérez-Hernández, JL; Pérez-Torres, E; Salas-Gordillo, F; Serralde-Zúñiga, AE; Servín-Caamaño, AI, 2015) |
| "The findings demonstrate that the efficacy of the pentoxifylline is not statistically equivalent to the efficacy of prednisolone, supporting the use of prednisolone as a preferred treatment option in patients with severe alcoholic hepatitis." | 9.19 | Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. ( Baik, SK; Jang, JY; Kim, DJ; Kim, HS; Kim, IH; Kim, SG; Kim, TY; Kim, YS; Lee, HJ; Lee, JS; Park, SH; Park, SY; Sohn, JH; Suh, SJ; Suk, KT; Tak, WY; Um, SH; Yim, HJ; Yoon, KT, 2014) |
| "In patients with alcoholic hepatitis, 4-week treatment with pentoxifylline and prednisolone, compared with prednisolone alone, did not result in improved 6-month survival." | 9.17 | Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. ( Anty, R; Boursier, J; Canva-Delcambre, V; Carbonell, N; Dao, T; Dharancy, S; Diaz, E; Duhamel, A; Lebrec, D; Louvet, A; Mathurin, P; Moirand, R; Moreno, C; Nahon, P; Naveau, S; Pageaux, GP; Paupard, T; Salleron, J; Silvain, C; Sobesky, R; Talbodec, N; Thabut, D, 2013) |
| "Corticosteroids and pentoxifylline reduce short-term mortality in severe alcoholic hepatitis (SAH), but not to the extent desired." | 9.16 | Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). ( Chhina, RS; Goyal, O; Gupta, D; Sidhu, SS; Singla, P; Soni, RK; Sood, A, 2012) |
| "To compare the efficacy of pentoxifylline and prednisolone in the treatment of severe alcoholic hepatitis, and to evaluate the role of different liver function scores in predicting prognosis." | 9.14 | Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. ( Baksi, SD; De, BK; Dutta, D; Gangopadhyay, S; Ghosh, P; Pani, A, 2009) |
| "An earlier pilot study from our liver unit suggested benefit from treatment with pentoxifylline (PTX), an inhibitor of tumor necrosis factor (TNF), in severe acute alcoholic hepatitis." | 9.09 | Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. ( Akriviadis, E; Botla, R; Briggs, W; Han, S; Reynolds, T; Shakil, O, 2000) |
| "We performed a meta-analysis of individual patient data from 11 randomized controlled trials comparing corticosteroids, pentoxifylline, or their combination in patients with severe alcoholic hepatitis." | 8.98 | Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials. ( Akriviadis, E; Atkinson, SR; Carithers, RL; Duhamel, A; Kim, DJ; Labreuche, J; Louvet, A; Maddrey, WC; Mathurin, P; Morgan, TR; O'Grady, JG; Ramond, MJ; Sidhu, SS; Sinakos, E; Thursz, MR, 2018) |
| "Although both corticosteroids and pentoxifylline are currently recommended drugs for the treatment of patients with severe alcoholic hepatitis, their effectiveness in reducing mortality remains unclear." | 8.95 | Treatment of Severe Alcoholic Hepatitis With Corticosteroid, Pentoxifylline, or Dual Therapy: A Systematic Review and Meta-Analysis. ( Bak, YT; Byun, KS; Joo, MK; Jung, YK; Kang, SH; Kim, HJ; Kim, JH; Kim, JS; Kim, TS; Lee, BJ; Lee, YS; Park, JJ; Seo, YS; Suh, SJ; Um, SH; Yeon, JE; Yim, HJ; Yoo, YJ, 2017) |
| "Despite better knowledge of the pathogenesis of severe alcoholic hepatitis (AH), corticosteroids are still the treatment recommended by clinical guidelines, pentoxifylline being the second-line option for non-responders to corticosteriods and for patients with contraindications." | 8.93 | [Is there a role for pentoxifylline in the treatment of alcoholic hepatitis?]. ( Caballeria, J, 2016) |
| "Pentoxifylline is an inhibitor of tumor necrosis factor, and has been proposed as treatment for alcoholic hepatitis." | 8.90 | Is pentoxifylline effective in alcoholic hepatitis? First update. ( Arteaga, M; Candia, R; Rada, G, 2014) |
| "A literature search was undertaken using MeSH terms 'hepatitis, alcoholic' and 'pentoxifylline' using the set operator AND." | 8.89 | Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. ( Armstrong, MJ; Corbett, C; Houlihan, DD; Parker, R; Rowe, IA, 2013) |
| "To assess the benefits and harms of pentoxifylline in alcoholic hepatitis." | 8.85 | Pentoxifylline for alcoholic hepatitis. ( Gluud, C; Rambaldi, A; Wetterslev, J; Whitfield, K, 2009) |
| " We present the first study to compare outcomes in patients of severe alcoholic hepatitis (SAH) on nutritional therapy, corticosteroids, pentoxifylline, and healthy donor fecal transplantation (FMT) and discuss distinct microbial community and microbiome metabolic functional changes after FMT." | 7.88 | Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. ( Augustine, P; Ganesan, K; Phadke, N; Philips, CA; Ranade, S, 2018) |
| "Although favourable results of pentoxifylline (PTX) used in treatment of severe alcoholic hepatitis patients with a Maddrey discriminant function score > or = 32 have been previously reported, it is not currently recommended as a first line treatment for alcoholic hepatitis owing to lack of evidence for its efficacy as compared to the standard treatment with corticosteroids." | 7.75 | Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? ( Assimakopoulos, SF; Labropoulou-Karatza, C; Thomopoulos, KC, 2009) |
| "Patients with alcoholic hepatitis (AH) have high mortality, so new therapies are needed." | 6.87 | Efficacy of Granulocyte Colony-Stimulating Factor and N-Acetylcysteine Therapies in Patients With Severe Alcoholic Hepatitis. ( Agarwal, R; Bhalla, A; Keisham, A; Sharma, N; Sharma, R; Singh, A; Singh, V, 2018) |
| "Role of corticosteroids in treatment of severe alcoholic hepatitis (SAH) is controversial." | 6.77 | Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. ( Bhatia, KL; Chhina, RS; Goyal, O; Sidhu, SS; Singla, M; Sood, A, 2012) |
| "In severe alcoholic hepatitis (AH), 40% of patients will obtain no benefit from corticosteroids." | 6.73 | Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. ( Canva, V; Coevoet, H; Deltenre, P; Dharancy, S; Diaz, E; Louvet, A; Mathurin, P; Plane, C; Texier, F; Thévenot, T, 2008) |
| "Alcoholic hepatitis (AH) markedly decreases the urea synthesis capacity." | 5.27 | Time course of compromised urea synthesis in patients with alcoholic hepatitis. ( Aagaard, NK; Glavind, E; Gronbaek, H; Orntoft, NW; Thomsen, KL; Vilstrup, H, 2018) |
| "Patients with SAH given prednisolone are at greater risk for developing serious infections and infections after treatment than patients not given prednisolone, which may offset its therapeutic benefit." | 5.24 | In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. ( Allison, M; Atkinson, SR; Austin, A; Forrest, EH; Gleeson, D; Knapp, S; Masson, S; Maurice, J; McCune, A; Patch, D; Richardson, P; Ryder, SD; Thursz, MR; Vergis, N; Wright, M, 2017) |
| "The aim of the clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis trial was to resolve the clinical dilemma on the use of prednisolone or PTX." | 5.20 | The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial. ( Allison, M; Austin, A; Bowers, M; Day, C; Downs, N; Forrest, E; Gleeson, D; Homer, T; Kirkman, S; Masson, S; McCune, A; Mellor, J; O'Grady, J; Patch, D; Ratcliffe, I; Richardson, P; Roderick, P; Ryder, S; Stanton, L; Ternent, L; Thursz, M; Vale, L; Wright, M, 2015) |
| "Pentoxifylline did not improve survival in patients with alcoholic hepatitis." | 5.20 | Prednisolone or pentoxifylline for alcoholic hepatitis. ( Allison, M; Austin, A; Bowers, M; Day, CP; Downs, N; Forrest, EH; Gleeson, D; Grant, A; Hood, S; MacGilchrist, A; Masson, S; McCune, A; Mellor, J; O'Grady, J; Patch, D; Ratcliffe, I; Richardson, P; Roderick, P; Ryder, S; Stanton, L; Thursz, MR; Vergis, N; Wright, M, 2015) |
| "To evaluate the impact of metadoxine (MTD) on the 3- and 6-mo survival of patients with severe alcoholic hepatitis (AH)." | 5.20 | Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. ( Abdo-Francis, JM; Cruz-Herrera, J; Higuera-de la Tijera, F; Pérez-Hernández, JL; Pérez-Torres, E; Salas-Gordillo, F; Serralde-Zúñiga, AE; Servín-Caamaño, AI, 2015) |
| "The findings demonstrate that the efficacy of the pentoxifylline is not statistically equivalent to the efficacy of prednisolone, supporting the use of prednisolone as a preferred treatment option in patients with severe alcoholic hepatitis." | 5.19 | Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. ( Baik, SK; Jang, JY; Kim, DJ; Kim, HS; Kim, IH; Kim, SG; Kim, TY; Kim, YS; Lee, HJ; Lee, JS; Park, SH; Park, SY; Sohn, JH; Suh, SJ; Suk, KT; Tak, WY; Um, SH; Yim, HJ; Yoon, KT, 2014) |
| "In patients with alcoholic hepatitis, 4-week treatment with pentoxifylline and prednisolone, compared with prednisolone alone, did not result in improved 6-month survival." | 5.17 | Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. ( Anty, R; Boursier, J; Canva-Delcambre, V; Carbonell, N; Dao, T; Dharancy, S; Diaz, E; Duhamel, A; Lebrec, D; Louvet, A; Mathurin, P; Moirand, R; Moreno, C; Nahon, P; Naveau, S; Pageaux, GP; Paupard, T; Salleron, J; Silvain, C; Sobesky, R; Talbodec, N; Thabut, D, 2013) |
| "Corticosteroids and pentoxifylline reduce short-term mortality in severe alcoholic hepatitis (SAH), but not to the extent desired." | 5.16 | Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). ( Chhina, RS; Goyal, O; Gupta, D; Sidhu, SS; Singla, P; Soni, RK; Sood, A, 2012) |
| "To compare the efficacy of pentoxifylline and prednisolone in the treatment of severe alcoholic hepatitis, and to evaluate the role of different liver function scores in predicting prognosis." | 5.14 | Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. ( Baksi, SD; De, BK; Dutta, D; Gangopadhyay, S; Ghosh, P; Pani, A, 2009) |
| "An earlier pilot study from our liver unit suggested benefit from treatment with pentoxifylline (PTX), an inhibitor of tumor necrosis factor (TNF), in severe acute alcoholic hepatitis." | 5.09 | Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. ( Akriviadis, E; Botla, R; Briggs, W; Han, S; Reynolds, T; Shakil, O, 2000) |
| "We performed a meta-analysis of individual patient data from 11 randomized controlled trials comparing corticosteroids, pentoxifylline, or their combination in patients with severe alcoholic hepatitis." | 4.98 | Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials. ( Akriviadis, E; Atkinson, SR; Carithers, RL; Duhamel, A; Kim, DJ; Labreuche, J; Louvet, A; Maddrey, WC; Mathurin, P; Morgan, TR; O'Grady, JG; Ramond, MJ; Sidhu, SS; Sinakos, E; Thursz, MR, 2018) |
| "Although both corticosteroids and pentoxifylline are currently recommended drugs for the treatment of patients with severe alcoholic hepatitis, their effectiveness in reducing mortality remains unclear." | 4.95 | Treatment of Severe Alcoholic Hepatitis With Corticosteroid, Pentoxifylline, or Dual Therapy: A Systematic Review and Meta-Analysis. ( Bak, YT; Byun, KS; Joo, MK; Jung, YK; Kang, SH; Kim, HJ; Kim, JH; Kim, JS; Kim, TS; Lee, BJ; Lee, YS; Park, JJ; Seo, YS; Suh, SJ; Um, SH; Yeon, JE; Yim, HJ; Yoo, YJ, 2017) |
| "Despite better knowledge of the pathogenesis of severe alcoholic hepatitis (AH), corticosteroids are still the treatment recommended by clinical guidelines, pentoxifylline being the second-line option for non-responders to corticosteriods and for patients with contraindications." | 4.93 | [Is there a role for pentoxifylline in the treatment of alcoholic hepatitis?]. ( Caballeria, J, 2016) |
| " Patients with severe acute alcoholic hepatitis, a distinct subset of alcoholic liver disease have a potential for mortality in about 25% within about 1 month despite treatment with available specific agents such as corticosteroids and/or pentoxifylline." | 4.90 | Current management of alcoholic liver disease. ( Jampana, SC; Singal, AK, 2014) |
| " Pentoxifylline is an effective alternative reducing the occurrence of hepatorenal syndrome." | 4.90 | Prognosis and treatment of patients with acute alcoholic hepatitis. ( Burroughs, AK; Papastergiou, V; Tsochatzis, EA, 2014) |
| "Pentoxifylline is an inhibitor of tumor necrosis factor, and has been proposed as treatment for alcoholic hepatitis." | 4.90 | Is pentoxifylline effective in alcoholic hepatitis? First update. ( Arteaga, M; Candia, R; Rada, G, 2014) |
| "A literature search was undertaken using MeSH terms 'hepatitis, alcoholic' and 'pentoxifylline' using the set operator AND." | 4.89 | Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. ( Armstrong, MJ; Corbett, C; Houlihan, DD; Parker, R; Rowe, IA, 2013) |
| "To assess the benefits and harms of pentoxifylline in alcoholic hepatitis." | 4.85 | Pentoxifylline for alcoholic hepatitis. ( Gluud, C; Rambaldi, A; Wetterslev, J; Whitfield, K, 2009) |
| "Participants in the Steroids or Pentoxifylline for Alcoholic Hepatitis trial with day zero (D0) creatinine available were included." | 4.31 | In severe alcohol-related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL-8 and micro-RNAs. ( Allison, M; Atkinson, S; Austin, A; Dear, JW; Forrest, E; Hunter, RW; Liu, T; Lord, E; Masson, S; Nunes, J; Richardson, P; Ryder, SD; Thursz, M; Tyson, LD; Vergis, N; Wright, M, 2023) |
| "To assess the utility of liver biopsy in the assessment of clinically severe AH METHODS: The histological features of alcoholic steatohepatitis (ASH) were recorded and scored in patients enrolled in the Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial who underwent liver biopsy." | 4.02 | The diagnostic and prognostic significance of liver histology in alcoholic hepatitis. ( Atkinson, S; Austin, A; Forrest, E; Goldin, R; Lloyd, K; Masson, S; Patch, D; Petts, G; Quaglia, A; Thursz, M; Vergis, N; Wright, M, 2021) |
| " We present the first study to compare outcomes in patients of severe alcoholic hepatitis (SAH) on nutritional therapy, corticosteroids, pentoxifylline, and healthy donor fecal transplantation (FMT) and discuss distinct microbial community and microbiome metabolic functional changes after FMT." | 3.88 | Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. ( Augustine, P; Ganesan, K; Phadke, N; Philips, CA; Ranade, S, 2018) |
| "To study the use of the Glasgow Alcoholic Hepatitis Score (GAHS), the Discriminant Function (DF), Model for End-Stage Liver Disease (MELD) and the ABIC (age, bilirubin, INR and creatinine) scores as well as scores to assess corticosteroid response in the management of alcoholic hepatitis." | 3.79 | The management of alcoholic hepatitis: a prospective comparison of scoring systems. ( Forrest, EH; Lafferty, H; Stanley, AJ, 2013) |
| "Although favourable results of pentoxifylline (PTX) used in treatment of severe alcoholic hepatitis patients with a Maddrey discriminant function score > or = 32 have been previously reported, it is not currently recommended as a first line treatment for alcoholic hepatitis owing to lack of evidence for its efficacy as compared to the standard treatment with corticosteroids." | 3.75 | Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? ( Assimakopoulos, SF; Labropoulou-Karatza, C; Thomopoulos, KC, 2009) |
| "Patients with alcoholic hepatitis (AH) have high mortality, so new therapies are needed." | 2.87 | Efficacy of Granulocyte Colony-Stimulating Factor and N-Acetylcysteine Therapies in Patients With Severe Alcoholic Hepatitis. ( Agarwal, R; Bhalla, A; Keisham, A; Sharma, N; Sharma, R; Singh, A; Singh, V, 2018) |
| "Role of corticosteroids in treatment of severe alcoholic hepatitis (SAH) is controversial." | 2.77 | Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. ( Bhatia, KL; Chhina, RS; Goyal, O; Sidhu, SS; Singla, M; Sood, A, 2012) |
| "In severe alcoholic hepatitis (AH), 40% of patients will obtain no benefit from corticosteroids." | 2.73 | Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. ( Canva, V; Coevoet, H; Deltenre, P; Dharancy, S; Diaz, E; Louvet, A; Mathurin, P; Plane, C; Texier, F; Thévenot, T, 2008) |
| "Clinicians caring for patients with alcoholic hepatitis (AH) are often confronted with the question of the best pharmacotherapy to be used." | 2.58 | Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options. ( Teschke, R, 2018) |
| "Severe alcoholic hepatitis (SAH) is defined by modified Maddrey discriminant function ≥32 or Model for End-Stage Liver Disease (MELD) >21 and/or hepatic encephalopathy." | 2.55 | New paradigms in management of alcoholic hepatitis: a review. ( Goyal, O; Kishore, H; Sidhu, S; Sidhu, SS, 2017) |
| "Alcoholic hepatitis is a severe acute manifestation of alcoholic liver disease with a high mortality." | 2.55 | Review article: recent insights into clinical decision-making in severe alcoholic hepatitis. ( Dunne, PDJ; Forrest, EH, 2017) |
| "Prednisolone has become the principal agent for treating patients with severe AH." | 2.53 | Acute Alcoholic Hepatitis: Therapy. ( Lucey, MR; Phillips, PK, 2016) |
| "Acute alcoholic hepatitis is a unique clinical syndrome among patients with chronic and active heavy alcohol use." | 2.53 | Therapeutic Strategies for the Treatment of Alcoholic Hepatitis. ( Shah, VH; Singal, AK, 2016) |
| "For patients with severe alcoholic hepatitis failing to medical therapy can be identified earlier and have a 6-month survival around 30%; early liver transplantation in those patients is attractive but highly controversial as it challenges the 6-month abstinence rule prior to LT." | 2.52 | Therapeutic management of alcoholic hepatitis. ( Mathurin, P, 2015) |
| "Severe alcoholic hepatitis (AH) has high mortality." | 2.52 | Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. ( Atkinson, SR; Bongiorno, CM; Chandar, AK; Loomba, R; Murad, MH; Shah, VH; Singal, AK; Singh, S; Thursz, MR, 2015) |
| "Severe alcoholic hepatitis is still associated with high mortality and presence of liver failure manifested by jaundice, coagulopathy and encephalopathy is a poor prognostic indicator." | 2.50 | [Management of severe alcoholic hepatitis]. ( Tilg, H; Wieser, V, 2014) |
| "Alcoholic hepatitis is a distinct clinical syndrome among people with chronic and active alcohol abuse, with a potential for 30%-40% mortality at 1 month among those with severe disease." | 2.50 | Alcoholic hepatitis: current challenges and future directions. ( Gores, GJ; Kamath, PS; Shah, VH; Singal, AK, 2014) |
| "Liver transplantation as the treatment of alcoholic hepatitis remains controversial, and in an era of organ shortage current guidelines do not recommend transplantation as the treatment option." | 2.50 | Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment. ( Chayanupatkul, M; Liangpunsakul, S, 2014) |
| "Pentoxifylline was found to reduce the risk of hepatorenal syndrome, but data on mortality are limited." | 2.49 | Update on the management of alcoholic steatohepatitis. ( Seitz, HK; Stickel, F, 2013) |
| "Alcoholic hepatitis is a frequent reason for admission and a common consultation request for hepatologists and gastroenterologists." | 2.48 | Alcoholic hepatitis: a clinician's guide. ( Choi, G; Runyon, BA, 2012) |
| "The diagnosis of alcoholic hepatitis can be made with a thorough history, physical examination, and review of laboratory results." | 2.48 | Diagnosis and management of alcoholic hepatitis. ( Satapathy, SK; Sohail, U, 2012) |
| "Alcoholic hepatitis is a severe form of alcohol-related liver injury and one of the most frequent liver presentations seen by acute medical services." | 2.48 | Alcoholic hepatitis: diagnosis and management in 2012. ( Potts, JR; Verma, S, 2012) |
| "Alcoholic hepatitis is a severe, cholestatic liver disease occurring in patients with alcohol abuse." | 2.45 | Review article: the diagnosis and management of alcoholic hepatitis. ( Ahn, J; Cohen, SM, 2009) |
| "The clinical spectrum of alcoholic hepatitis is wide and ranges from the asymptomatic patient to overt liver failure and death." | 2.45 | Controversies in the management of alcoholic liver disease. ( Martin, P; Tan, HH; Virmani, S, 2009) |
| "Alcoholic hepatitis is an increasingly common reason for hospital admission which carries a high mortality." | 2.45 | The management of alcoholic hepatitis. ( Forrest, EH, 2009) |
| "Alcoholic hepatitis is a disease with a wide range of severity." | 2.44 | Alcoholic steatohepatitis: management and prognosis. ( Maher, JJ, 2007) |
| "Alcoholic hepatitis is a serious complication of alcohol abuse due to its high mortality rates particularly at short term." | 2.43 | Alcoholic hepatitis: from pathogenesis to treatment. ( Dalakas, E; Hayes, PC; Plevris, JN; Sougioultzis, S, 2005) |
| "Although the classical treatment for alcoholic hepatitis is abstinence, in some individuals abstinence alone is inadequate to promote survival and recovery." | 2.41 | Treatment of alcoholic hepatitis. ( Maher, JJ, 2002) |
| "During alcoholic hepatitis (AH) monocytes traverse the vascular boundaries and massively invade the liver." | 1.48 | Decreased monocyte shedding of the migration inhibitor soluble CD18 in alcoholic hepatitis. ( Deleuran, B; Hansen, AL; Kragstrup, TW; Sandahl, TD; Støy, S; Vilstrup, H; Vorup-Jensen, T, 2018) |
| "Although short-term outcome in severe alcoholic hepatitis (SAH) is well described, its long-term course remains uncharacterised." | 1.39 | Determinants of long-term outcome in severe alcoholic hepatitis. ( Goubet, S; Heneghan, MA; Potts, JR; Verma, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (23.53) | 29.6817 |
| 2010's | 59 (69.41) | 24.3611 |
| 2020's | 6 (7.06) | 2.80 |
| Authors | Studies |
|---|---|
| Szabo, G | 1 |
| Mitchell, M | 1 |
| McClain, CJ | 3 |
| Dasarathy, S | 2 |
| Barton, B | 1 |
| McCullough, AJ | 3 |
| Nagy, LE | 1 |
| Kroll-Desrosiers, A | 1 |
| Tornai, D | 1 |
| Min, HA | 1 |
| Radaeva, S | 1 |
| Holbein, MEB | 1 |
| Casey, L | 1 |
| Cuthbert, J | 1 |
| Gupta, S | 1 |
| Nath, P | 1 |
| Anand, AC | 1 |
| Singh, SP | 1 |
| Mishra, AK | 1 |
| Jindal, A | 1 |
| Tyson, LD | 1 |
| Atkinson, S | 2 |
| Hunter, RW | 1 |
| Allison, M | 4 |
| Austin, A | 5 |
| Dear, JW | 1 |
| Forrest, E | 3 |
| Liu, T | 1 |
| Lord, E | 1 |
| Masson, S | 5 |
| Nunes, J | 1 |
| Richardson, P | 4 |
| Ryder, SD | 2 |
| Wright, M | 5 |
| Thursz, M | 3 |
| Vergis, N | 4 |
| Petts, G | 1 |
| Lloyd, K | 1 |
| Patch, D | 4 |
| Quaglia, A | 1 |
| Goldin, R | 1 |
| Maddur, H | 1 |
| Dunne, PDJ | 1 |
| Forrest, EH | 6 |
| Rana, R | 1 |
| Wang, SL | 1 |
| Li, J | 1 |
| Xia, L | 1 |
| Song, MY | 1 |
| Yang, CQ | 1 |
| Woolbright, BL | 1 |
| Bridges, BW | 1 |
| Dunn, W | 1 |
| Olson, JC | 1 |
| Weinman, SA | 1 |
| Jaeschke, H | 1 |
| Glavind, E | 1 |
| Aagaard, NK | 1 |
| Gronbaek, H | 1 |
| Orntoft, NW | 1 |
| Vilstrup, H | 2 |
| Thomsen, KL | 1 |
| Singh, V | 1 |
| Keisham, A | 1 |
| Bhalla, A | 1 |
| Sharma, N | 1 |
| Agarwal, R | 1 |
| Sharma, R | 1 |
| Singh, A | 1 |
| Teschke, R | 1 |
| Louvet, A | 4 |
| Thursz, MR | 5 |
| Kim, DJ | 2 |
| Labreuche, J | 1 |
| Atkinson, SR | 3 |
| Sidhu, SS | 5 |
| O'Grady, JG | 1 |
| Akriviadis, E | 2 |
| Sinakos, E | 1 |
| Carithers, RL | 1 |
| Ramond, MJ | 1 |
| Maddrey, WC | 1 |
| Morgan, TR | 3 |
| Duhamel, A | 2 |
| Mathurin, P | 6 |
| Støy, S | 1 |
| Sandahl, TD | 1 |
| Hansen, AL | 1 |
| Deleuran, B | 1 |
| Vorup-Jensen, T | 1 |
| Kragstrup, TW | 1 |
| Philips, CA | 1 |
| Phadke, N | 1 |
| Ganesan, K | 1 |
| Ranade, S | 1 |
| Augustine, P | 1 |
| Obed, A | 1 |
| Bashir, A | 1 |
| Stern, S | 1 |
| Jarrad, A | 1 |
| Parker, R | 1 |
| Armstrong, MJ | 1 |
| Corbett, C | 1 |
| Rowe, IA | 2 |
| Houlihan, DD | 1 |
| Stickel, F | 1 |
| Seitz, HK | 1 |
| Singal, AK | 5 |
| Kamath, PS | 1 |
| Gores, GJ | 1 |
| Shah, VH | 3 |
| Wieser, V | 1 |
| Tilg, H | 1 |
| Lafferty, H | 1 |
| Stanley, AJ | 1 |
| Potts, JR | 2 |
| Goubet, S | 1 |
| Heneghan, MA | 1 |
| Verma, S | 2 |
| Halegoua-De Marzio, DL | 1 |
| Fenkel, JM | 1 |
| Nahon, P | 1 |
| Carbonell, N | 1 |
| Boursier, J | 1 |
| Anty, R | 1 |
| Diaz, E | 2 |
| Thabut, D | 1 |
| Moirand, R | 1 |
| Lebrec, D | 1 |
| Moreno, C | 1 |
| Talbodec, N | 1 |
| Paupard, T | 1 |
| Naveau, S | 1 |
| Silvain, C | 1 |
| Pageaux, GP | 1 |
| Sobesky, R | 1 |
| Canva-Delcambre, V | 1 |
| Dharancy, S | 2 |
| Salleron, J | 1 |
| Dao, T | 1 |
| Joshi, P | 1 |
| Manori, P | 1 |
| Bajpai, P | 1 |
| Goyal, O | 4 |
| Raff, E | 1 |
| Casanova, J | 1 |
| Bataller, R | 1 |
| Papastergiou, V | 1 |
| Burroughs, AK | 1 |
| Tsochatzis, EA | 1 |
| Park, SH | 1 |
| Kim, YS | 1 |
| Yim, HJ | 2 |
| Tak, WY | 1 |
| Lee, HJ | 1 |
| Sohn, JH | 1 |
| Yoon, KT | 1 |
| Kim, IH | 1 |
| Kim, HS | 1 |
| Um, SH | 2 |
| Baik, SK | 1 |
| Lee, JS | 1 |
| Suk, KT | 1 |
| Kim, SG | 1 |
| Suh, SJ | 2 |
| Park, SY | 1 |
| Kim, TY | 1 |
| Jang, JY | 1 |
| Chayanupatkul, M | 1 |
| Liangpunsakul, S | 1 |
| Jampana, SC | 1 |
| Rada, G | 2 |
| Arteaga, M | 2 |
| Candia, R | 1 |
| Caballeria, J | 4 |
| Kim, W | 1 |
| Chanson, P | 1 |
| Pariente, A | 1 |
| Townsend, SA | 1 |
| Elsharkawy, AM | 1 |
| Bowers, M | 2 |
| Day, CP | 1 |
| Downs, N | 2 |
| Gleeson, D | 3 |
| MacGilchrist, A | 1 |
| Grant, A | 1 |
| Hood, S | 1 |
| McCune, A | 3 |
| Mellor, J | 2 |
| O'Grady, J | 2 |
| Ratcliffe, I | 2 |
| Roderick, P | 2 |
| Stanton, L | 2 |
| Ryder, S | 3 |
| Higuera-de la Tijera, F | 1 |
| Servín-Caamaño, AI | 1 |
| Serralde-Zúñiga, AE | 1 |
| Cruz-Herrera, J | 1 |
| Pérez-Torres, E | 1 |
| Abdo-Francis, JM | 1 |
| Salas-Gordillo, F | 1 |
| Pérez-Hernández, JL | 1 |
| Singh, S | 1 |
| Murad, MH | 1 |
| Chandar, AK | 1 |
| Bongiorno, CM | 1 |
| Loomba, R | 1 |
| Verbeke, L | 1 |
| Laleman, W | 1 |
| Nevens, F | 1 |
| DiNubile, MJ | 1 |
| Parikh, ND | 1 |
| Schlansky, B | 1 |
| Day, C | 1 |
| Vale, L | 1 |
| Kirkman, S | 1 |
| Homer, T | 1 |
| Ternent, L | 1 |
| Shasthry, SM | 1 |
| Sarin, SK | 1 |
| Nguyen, TA | 1 |
| DeShazo, JP | 1 |
| Thacker, LR | 1 |
| Puri, P | 1 |
| Sanyal, AJ | 1 |
| Phillips, PK | 1 |
| Lucey, MR | 3 |
| Lee, YS | 1 |
| Kim, HJ | 1 |
| Kim, JH | 1 |
| Yoo, YJ | 1 |
| Kim, TS | 1 |
| Kang, SH | 1 |
| Joo, MK | 1 |
| Jung, YK | 1 |
| Lee, BJ | 1 |
| Seo, YS | 1 |
| Yeon, JE | 1 |
| Kim, JS | 1 |
| Park, JJ | 1 |
| Bak, YT | 1 |
| Byun, KS | 1 |
| Knapp, S | 1 |
| Maurice, J | 1 |
| Kishore, H | 1 |
| Sidhu, S | 1 |
| Ghavami, P | 1 |
| Neher, JO | 1 |
| St Anna, L | 1 |
| De, BK | 1 |
| Gangopadhyay, S | 1 |
| Dutta, D | 1 |
| Baksi, SD | 1 |
| Pani, A | 1 |
| Ghosh, P | 1 |
| Cohen, SM | 1 |
| Ahn, J | 1 |
| Assimakopoulos, SF | 1 |
| Thomopoulos, KC | 1 |
| Labropoulou-Karatza, C | 1 |
| Tan, HH | 1 |
| Virmani, S | 1 |
| Martin, P | 1 |
| Whitfield, K | 1 |
| Rambaldi, A | 1 |
| Wetterslev, J | 1 |
| Gluud, C | 1 |
| Amini, M | 1 |
| Runyon, BA | 2 |
| O'Shea, RS | 1 |
| Singla, P | 1 |
| Gupta, D | 1 |
| Sood, A | 2 |
| Chhina, RS | 2 |
| Soni, RK | 1 |
| Choi, G | 1 |
| Singla, M | 1 |
| Bhatia, KL | 1 |
| Sohail, U | 1 |
| Satapathy, SK | 1 |
| Dhanda, AD | 1 |
| Lee, RW | 1 |
| Collins, PL | 1 |
| McCune, CA | 1 |
| Julkunen, R | 1 |
| Hill, DB | 1 |
| Parés, A | 1 |
| Zhang, FK | 1 |
| Zhang, JY | 1 |
| Jia, JD | 1 |
| Sougioultzis, S | 1 |
| Dalakas, E | 1 |
| Hayes, PC | 1 |
| Plevris, JN | 1 |
| O'Shea, R | 1 |
| Maher, JJ | 2 |
| Coevoet, H | 1 |
| Texier, F | 1 |
| Thévenot, T | 1 |
| Deltenre, P | 1 |
| Canva, V | 1 |
| Plane, C | 1 |
| Botla, R | 1 |
| Briggs, W | 1 |
| Han, S | 1 |
| Reynolds, T | 1 |
| Shakil, O | 1 |
| Karnam, US | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis[NCT01809132] | Phase 2/Phase 3 | 104 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis[NCT02971306] | Phase 4 | 60 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis[NCT02281929] | Phase 3 | 297 participants (Actual) | Interventional | 2015-06-13 | Completed | ||
| Evaluation of the Survival Benefit of the Adjunction of Pentoxifylline to Corticosteroids in Patients Suffering From Severe Alcoholic Hepatitis[NCT01214226] | Phase 3 | 278 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Effect of Omega-5 Fatty Acid Supplement on Markers of Inflammation and Oxidative Stress in Patients With Severe Alcoholic Hepatitis Treated With Prednisone[NCT03732586] | 40 participants (Actual) | Interventional | 2018-09-30 | Completed | |||
| U01 Pilot Trial of DUR-928 in Patients With Moderate and Severe Alcoholic Hepatitis[NCT03917407] | Phase 2 | 43 participants (Actual) | Interventional | 2021-06-01 | Completed | ||
| Digoxin In Treatment of Alcohol Associated Hepatitis (DIGIT-AlcHep)[NCT05014087] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-10-08 | Recruiting | ||
| Corticosteroids in Severe Alcoholic Hepatitis Patients With Early Spontaneous Improvement[NCT03160651] | 140 participants (Anticipated) | Interventional | 2018-02-09 | Recruiting | |||
| Impact of Metadoxine in the Oxidative Stress and Early Mortality in Patients With Severe Alcoholic Hepatitis[NCT02161653] | Phase 4 | 135 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| The Effects of Dexamethasone Administration on Jaundice Following Liver Resection: a Randomized Controlled Trial[NCT02991339] | Phase 2/Phase 3 | 76 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial[NCT02473341] | Phase 3 | 174 participants (Actual) | Interventional | 2017-11-14 | Active, not recruiting | ||
| Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study[NCT02123576] | 12 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Poor enrollment of study population) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Death at 180 days (NCT01809132)
Timeframe: Time to event up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Anakinra & Pentoxifylline & Zinc Sulfate | 17 |
| Methylprednisolone | 22 |
| Observational | 0 |
"Model of End Stage Liver Disease Score calculated from serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR). MELD score ranges from 6-40. A higher score indicates a lesser outcome.~The Model for End Stage Liver Disease scoring system is based on the INR, total serum bilirubin and serum creatinine. The measure reflects 90 day prognosis of alcohol associated liver disease from the time of measurement and therefore can only be assessed on subjects who are alive at the specified time point since lab values from that time point are required for the measure." (NCT01809132)
Timeframe: 180 Days
| Intervention | score on a scale (Mean) |
|---|---|
| Anakinra & Pentoxifylline & Zinc Sulfate | 15.81 |
| Methylprednisolone | 11.85 |
"Model of End Stage Liver Disease Score calculated from serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR). MELD score ranges from 6-40. A higher score indicates a lesser outcome.~The Model for End Stage Liver Disease scoring system is based on the INR, total serum bilirubin and serum creatinine. The measure reflects 90 day prognosis of alcohol associated liver disease from the time of measurement and therefore can only be assessed on subjects who are alive at the specified time point since lab values from that time point are required for the measure." (NCT01809132)
Timeframe: 28 days
| Intervention | score on a scale (Mean) |
|---|---|
| Anakinra & Pentoxifylline & Zinc Sulfate | 22.57 |
| Methylprednisolone | 20.95 |
"Model of End Stage Liver Disease Score calculated from serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR). MELD score ranges from 6-40. A higher score indicates a lesser outcome.~The Model for End Stage Liver Disease scoring system is based on the INR, total serum bilirubin and serum creatinine. The measure reflects 90 day prognosis of alcohol associated liver disease from the time of measurement and therefore can only be assessed on subjects who are alive at the specified time point since lab values from that time point are required for the measure." (NCT01809132)
Timeframe: 90 Days
| Intervention | score on a scale (Mean) |
|---|---|
| Anakinra & Pentoxifylline & Zinc Sulfate | 15.50 |
| Methylprednisolone | 16.38 |
(NCT02123576)
Timeframe: baseline and 14 days
| Intervention | g/dL (Mean) |
|---|---|
| Treatment | 0.48 |
| Placebo | 0.03 |
Defined as creatinine level above baseline value after day 7, dialysis or death (NCT02123576)
Timeframe: up to day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 3 |
| Placebo | 3 |
We define as serum creatinine level decreased by >50% from baseline but not to <1.5 mg/dL, without dialysis or HRS recurrence (NCT02123576)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Placebo | 2 |
We define this as a decrease in serum creatinine level to <1.5 mg/dL without dialysis or death (NCT02123576)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Placebo | 1 |
This will be the combination of transplant free survival and those patients who received liver transplant (NCT02123576)
Timeframe: up to 1 year
| Intervention | days (Mean) |
|---|---|
| Treatment | 102 |
| Placebo | 59 |
(NCT02123576)
Timeframe: day 30 and 180
| Intervention | days (Mean) |
|---|---|
| Treatment | 80 |
| Placebo | 36 |
44 reviews available for pentoxifylline and Alcoholic Hepatitis
| Article | Year |
|---|---|
Current Therapies for Alcohol-Associated Hepatitis.
Topics: Adrenal Cortex Hormones; Granulocyte Colony-Stimulating Factor; Hepatitis, Alcoholic; Humans; Liver | 2021 |
Review article: recent insights into clinical decision-making in severe alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Bilirubin; Clinical Decision-Making; Hepatitis, Alcoholic; Humans; Liver Tr | 2017 |
A prognostic evaluation and management of alcoholic hepatitis.
Topics: Acetylcysteine; Adrenal Cortex Hormones; Alcohol Abstinence; Bilirubin; Biomarkers; Biopsy; Combined | 2017 |
Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options.
Topics: Alcohol Abstinence; Alcohol Dehydrogenase; Catalase; Fatty Liver, Alcoholic; Hepatitis, Alcoholic; H | 2018 |
Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials.
Topics: Drug Therapy, Combination; Glucocorticoids; Hepatitis, Alcoholic; Humans; Pentoxifylline; Placebos; | 2018 |
Severe acute alcoholic hepatitis and liver transplant: A never-ending mournful story.
Topics: Alcohol Dehydrogenase; Alcoholism; Hepatitis, Alcoholic; Humans; Liver Transplantation; Pentoxifylli | 2018 |
Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis.
Topics: Hepatitis, Alcoholic; Humans; Pentoxifylline; Phosphodiesterase Inhibitors; Prognosis; Randomized Co | 2013 |
Update on the management of alcoholic steatohepatitis.
Topics: Acetylcysteine; Adrenal Cortex Hormones; Alcohol Abstinence; Animals; Enteral Nutrition; Fatty Liver | 2013 |
Alcoholic hepatitis: current challenges and future directions.
Topics: Adrenal Cortex Hormones; Alcoholism; Anti-Inflammatory Agents; Free Radical Scavengers; Hepatitis, A | 2014 |
[Management of severe alcoholic hepatitis].
Topics: Alcoholism; Antibodies, Monoclonal; Combined Modality Therapy; Etanercept; Fatty Liver, Alcoholic; F | 2014 |
Optimal management of alcoholic hepatitis.
Topics: Algorithms; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Hepatitis, Alcoholi | 2014 |
Alcoholic hepatitis: Prognosis and treatment.
Topics: Alcohol Deterrents; Animals; Antibodies, Monoclonal; Disease Models, Animal; Etanercept; Fatty Liver | 2014 |
Prognosis and treatment of patients with acute alcoholic hepatitis.
Topics: Acetylcysteine; Acute Disease; Adrenal Cortex Hormones; Antioxidants; Drug Resistance; Drug Therapy, | 2014 |
Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment.
Topics: Acetylcysteine; Adrenal Cortex Hormones; Alcoholism; End Stage Liver Disease; Enteral Nutrition; Hep | 2014 |
Current management of alcoholic liver disease.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antioxidants; Caspase Inhibitors; Etanercept; Hepat | 2014 |
Is pentoxifylline effective in alcoholic hepatitis? First update.
Topics: Adrenal Cortex Hormones; Glucocorticoids; Hepatitis, Alcoholic; Humans; Pentoxifylline; Phosphodiest | 2014 |
Is pentoxifylline effective in alcoholic hepatitis? First update.
Topics: Adrenal Cortex Hormones; Glucocorticoids; Hepatitis, Alcoholic; Humans; Pentoxifylline; Phosphodiest | 2014 |
Is pentoxifylline effective in alcoholic hepatitis? First update.
Topics: Adrenal Cortex Hormones; Glucocorticoids; Hepatitis, Alcoholic; Humans; Pentoxifylline; Phosphodiest | 2014 |
Is pentoxifylline effective in alcoholic hepatitis? First update.
Topics: Adrenal Cortex Hormones; Glucocorticoids; Hepatitis, Alcoholic; Humans; Pentoxifylline; Phosphodiest | 2014 |
[Diagnostic and therapeutic strategies for severe alcoholic hepatitis].
Topics: Adrenal Cortex Hormones; Free Radical Scavengers; Hepatitis, Alcoholic; Humans; Liver Transplantatio | 2015 |
Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis.
Topics: Acetylcysteine; Adrenal Cortex Hormones; Comparative Effectiveness Research; Disease Progression; Dr | 2015 |
Therapeutic management of alcoholic hepatitis.
Topics: Alcohol Abstinence; Enteral Nutrition; Free Radical Scavengers; Glucocorticoids; Hepatitis, Alcoholi | 2015 |
[Is there a role for pentoxifylline in the treatment of alcoholic hepatitis?].
Topics: Adrenal Cortex Hormones; Clinical Trials as Topic; Drug Resistance; Drug Therapy, Combination; Hepat | 2016 |
Therapeutic Strategies for the Treatment of Alcoholic Hepatitis.
Topics: Adrenal Cortex Hormones; Alcohol Abstinence; Animals; Anti-Inflammatory Agents; Hepatitis, Alcoholic | 2016 |
New treatment options for alcoholic hepatitis.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Drug Resistance; Gastrointestinal Microbiome; Gastr | 2016 |
Acute Alcoholic Hepatitis: Therapy.
Topics: Acute Disease; Alcohol Abstinence; Antioxidants; Glucocorticoids; Hepatitis, Alcoholic; Humans; Live | 2016 |
Treatment of Severe Alcoholic Hepatitis With Corticosteroid, Pentoxifylline, or Dual Therapy: A Systematic Review and Meta-Analysis.
Topics: Adrenal Cortex Hormones; Drug Therapy, Combination; Free Radical Scavengers; Hepatitis, Alcoholic; H | 2017 |
New paradigms in management of alcoholic hepatitis: a review.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Fecal Microbiota Transplantation; Female | 2017 |
Review article: the diagnosis and management of alcoholic hepatitis.
Topics: Anabolic Agents; Anti-Inflammatory Agents; Antioxidants; Hepatitis, Alcoholic; Humans; Liver Transpl | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Diagnosis, Differential; Hepatitis, Alcoholic; Hu | 2009 |
Controversies in the management of alcoholic liver disease.
Topics: Alcoholism; Glucocorticoids; Hepatitis, Alcoholic; Humans; Liver; Liver Diseases, Alcoholic; Liver T | 2009 |
Pentoxifylline for alcoholic hepatitis.
Topics: Cause of Death; Hepatitis, Alcoholic; Humans; Pentoxifylline; Randomized Controlled Trials as Topic; | 2009 |
The management of alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Epidemiologic Methods; Hepatitis, Alcoholic; Huma | 2009 |
Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy.
Topics: Alcohol Deterrents; Alcohol Drinking; Anti-Inflammatory Agents; Baclofen; Combined Modality Therapy; | 2010 |
Diagnosis and management of alcoholic liver disease.
Topics: Adrenal Cortex Hormones; Hepatitis, Alcoholic; Humans; Liver Diseases, Alcoholic; Liver Transplantat | 2011 |
Management of alcoholic hepatitis.
Topics: Acetylcysteine; Adrenal Cortex Hormones; Alcohol Drinking; Enteral Nutrition; Free Radical Scavenger | 2012 |
Alcoholic hepatitis: a clinician's guide.
Topics: Adrenal Cortex Hormones; Anabolic Agents; Baclofen; Dietary Supplements; GABA-B Receptor Agonists; H | 2012 |
Diagnosis and management of alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Antioxidants; Biopsy; Hepatitis, Alcoholic; Humans; Liver; Liver Regenerati | 2012 |
Molecular targets in the treatment of alcoholic hepatitis.
Topics: Animals; Hepatitis, Alcoholic; Humans; Molecular Targeted Therapy; Pentoxifylline; Phosphodiesterase | 2012 |
Alcoholic hepatitis: diagnosis and management in 2012.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Biopsy; He | 2012 |
[Treatment of alcohol hepatitis].
Topics: Adrenal Cortex Hormones; Clinical Trials as Topic; Cytokines; Hepatitis, Alcoholic; Humans; Pentoxif | 2003 |
[Physiopathological bases for the treatment of acute alcoholic hepatitis].
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Alcoholism; Anabolic Agents; Antibodies, Monoclonal; | 2004 |
Treatment of patients with alcoholic liver disease.
Topics: Adrenal Cortex Hormones; Antioxidants; Combined Modality Therapy; Drug Therapy, Combination; Female; | 2005 |
Alcoholic hepatitis: from pathogenesis to treatment.
Topics: Adrenal Cortex Hormones; Diet Therapy; Free Radical Scavengers; Hepatitis, Alcoholic; Humans; Liver | 2005 |
Alcoholic steatohepatitis: management and prognosis.
Topics: Adrenal Cortex Hormones; Fatty Liver, Alcoholic; Hepatitis, Alcoholic; Humans; Nutritional Support; | 2007 |
Pentoxifylline and alcoholic hepatitis.
Topics: Animals; Hepatitis, Alcoholic; Humans; Pentoxifylline; Phosphodiesterase Inhibitors; Randomized Cont | 2000 |
Treatment of alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Antimetabolites; Antioxidants; Colchicine; Hepatitis, Alcoholic; Humans; Li | 2002 |
15 trials available for pentoxifylline and Alcoholic Hepatitis
| Article | Year |
|---|---|
IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis.
Topics: Adrenal Cortex Hormones; Adult; End Stage Liver Disease; Female; Hepatitis, Alcoholic; Humans; Inter | 2022 |
Time course of compromised urea synthesis in patients with alcoholic hepatitis.
Topics: Adult; Blood Glucose; Denmark; Female; Glucagon; Glucocorticoids; Hepatitis, Alcoholic; Humans; Insu | 2018 |
Efficacy of Granulocyte Colony-Stimulating Factor and N-Acetylcysteine Therapies in Patients With Severe Alcoholic Hepatitis.
Topics: Acetylcysteine; Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Free Radical Scavengers; | 2018 |
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial.
Topics: Double-Blind Method; Drug Therapy, Combination; Female; Free Radical Scavengers; Glucocorticoids; He | 2013 |
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial.
Topics: Double-Blind Method; Drug Therapy, Combination; Female; Free Radical Scavengers; Glucocorticoids; He | 2013 |
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial.
Topics: Double-Blind Method; Drug Therapy, Combination; Female; Free Radical Scavengers; Glucocorticoids; He | 2013 |
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial.
Topics: Double-Blind Method; Drug Therapy, Combination; Female; Free Radical Scavengers; Glucocorticoids; He | 2013 |
Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial.
Topics: Adult; Anti-Inflammatory Agents; Drug Monitoring; Female; Gastrointestinal Hemorrhage; Hepatitis, Al | 2014 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Prednisolone or pentoxifylline for alcoholic hepatitis.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Glucocorticoids; Hepatitis, Alcoholic; Hum | 2015 |
Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis.
Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Drug Administration Schedule; Drug Combinations; Drug | 2015 |
Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis.
Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Drug Administration Schedule; Drug Combinations; Drug | 2015 |
Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis.
Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Drug Administration Schedule; Drug Combinations; Drug | 2015 |
Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis.
Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Drug Administration Schedule; Drug Combinations; Drug | 2015 |
The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial.
Topics: Adult; Aged; Alcohol Drinking; Cost-Benefit Analysis; Double-Blind Method; Female; Glucocorticoids; | 2015 |
In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA.
Topics: Adult; Anti-Bacterial Agents; Disease Susceptibility; DNA, Bacterial; Double-Blind Method; Female; F | 2017 |
Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial.
Topics: Adult; Aged; Anti-Inflammatory Agents; Double-Blind Method; Female; Hepatitis, Alcoholic; Humans; Ma | 2009 |
Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial).
Topics: Adrenal Cortex Hormones; Adult; Aged; Analysis of Variance; Cause of Death; Disease-Free Survival; D | 2012 |
Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial.
Topics: Adult; Aged; Hepatitis, Alcoholic; Humans; Kidney; Liver; Middle Aged; Pentoxifylline; Phosphodieste | 2012 |
Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids.
Topics: Adrenal Cortex Hormones; Adult; Aged; Bilirubin; Cohort Studies; Creatinine; Drug Resistance; Female | 2008 |
Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Cohort Studies; Disease Progression; Double-Blind Method; Female; Hepatitis, A | 2000 |
A toast to pentoxifylline.
Topics: Acute Disease; Double-Blind Method; Hepatitis, Alcoholic; Humans; Pentoxifylline; Phosphodiesterase | 2001 |
26 other studies available for pentoxifylline and Alcoholic Hepatitis
| Article | Year |
|---|---|
Letter to the editor: Combination treatment with IL-1 antagonist, pentoxifylline and zinc for severe alcoholic hepatitis: Are we there yet?
Topics: Hepatitis, Alcoholic; Humans; Interleukin-1; Pentoxifylline; Prednisolone; Zinc | 2022 |
Letter to the editor: IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcoholic hepatitis-More questions than answers!
Topics: Hepatitis, Alcoholic; Humans; Pentoxifylline; Prednisolone; Receptors, Interleukin-1; Zinc | 2022 |
In severe alcohol-related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL-8 and micro-RNAs.
Topics: Acute Kidney Injury; Biomarkers; Hepatitis, Alcoholic; Humans; Interleukin-8; MicroRNAs; Patient Acu | 2023 |
The diagnostic and prognostic significance of liver histology in alcoholic hepatitis.
Topics: Fatty Liver, Alcoholic; Hepatitis, Alcoholic; Humans; Liver; Pentoxifylline; Prognosis; Randomized C | 2021 |
Cell Death and Prognosis of Mortality in Alcoholic Hepatitis Patients Using Plasma Keratin-18.
Topics: Adrenal Cortex Hormones; Adult; Animals; Biomarkers; Cell Death; Female; Hepatitis, Alcoholic; Human | 2017 |
Decreased monocyte shedding of the migration inhibitor soluble CD18 in alcoholic hepatitis.
Topics: Animals; CD18 Antigens; Cell Movement; Cells, Cultured; Ethanol; Female; Hepatitis, Alcoholic; Human | 2018 |
Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis.
Topics: Administration, Oral; Adult; Aged; Fecal Microbiota Transplantation; Feces; Female; Gastrointestinal | 2018 |
The management of alcoholic hepatitis: a prospective comparison of scoring systems.
Topics: Adult; Aged; Aged, 80 and over; Bilirubin; Blood Proteins; Glucocorticoids; Hepatitis, Alcoholic; Hu | 2013 |
Determinants of long-term outcome in severe alcoholic hepatitis.
Topics: Adult; Aged; Alcohol Drinking; Drug Therapy, Combination; Female; Glucocorticoids; Hepatitis, Alcoho | 2013 |
Treatment of severe alcoholic hepatitis with corticosteroids and pentoxifylline.
Topics: Female; Free Radical Scavengers; Glucocorticoids; Hepatitis, Alcoholic; Humans; Male; Pentoxifylline | 2013 |
Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial.
Topics: Hepatitis, Alcoholic; Humans; Pentoxifylline; Phosphodiesterase Inhibitors | 2013 |
Author's reply: To PMID 23029716.
Topics: Hepatitis, Alcoholic; Humans; Pentoxifylline; Phosphodiesterase Inhibitors | 2013 |
Prednisolone vs. pentoxifylline for severe alcoholic hepatitis.
Topics: Anti-Inflammatory Agents; Hepatitis, Alcoholic; Humans; Patient Selection; Pentoxifylline; Phosphodi | 2014 |
Is petoxifylline still an option in severe alcoholic hepatitis?
Topics: Female; Hepatitis, Alcoholic; Humans; Male; Pentoxifylline; Prednisolone | 2015 |
[Pentoxifylline against prednisolone in severe acute alcoholic hepatitis: a Korean trial].
Topics: Acute Disease; Adult; Hepatitis, Alcoholic; Humans; Multicenter Studies as Topic; Pentoxifylline; Pr | 2014 |
Reply: To PMID 25502967.
Topics: Female; Hepatitis, Alcoholic; Humans; Male; Pentoxifylline; Prednisolone | 2015 |
Is pentoxifylline still an option in severe alcoholic hepatitis?
Topics: Female; Hepatitis, Alcoholic; Humans; Male; Pentoxifylline; Prednisolone | 2015 |
Prednisolone or Pentoxifylline for Alcoholic Hepatitis.
Topics: Female; Glucocorticoids; Hepatitis, Alcoholic; Humans; Male; Pentoxifylline; Prednisolone | 2015 |
Prednisolone or Pentoxifylline for Alcoholic Hepatitis.
Topics: Female; Glucocorticoids; Hepatitis, Alcoholic; Humans; Male; Pentoxifylline; Prednisolone | 2015 |
Prednisolone or Pentoxifylline for Alcoholic Hepatitis.
Topics: Female; Glucocorticoids; Hepatitis, Alcoholic; Humans; Male; Pentoxifylline; Prednisolone | 2015 |
Comparative Effectiveness of Medical Therapies for Severe Alcoholic Hepatitis: Guidance at Last?
Topics: Acetylcysteine; Adrenal Cortex Hormones; Free Radical Scavengers; Hepatitis, Alcoholic; Humans; Pent | 2015 |
The Worsening Profile of Alcoholic Hepatitis in the United States.
Topics: Adult; Aged; Comorbidity; Databases, Factual; Female; Hepatitis, Alcoholic; Hospitalization; Humans; | 2016 |
Clinical inquiries. How does pentoxifylline affect survival of patients with alcoholic hepatitis?
Topics: Adult; Evidence-Based Medicine; Female; Hepatitis, Alcoholic; Humans; Male; Pentoxifylline; Randomiz | 2008 |
Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome?
Topics: Hepatitis, Alcoholic; Hepatorenal Syndrome; Humans; Pentoxifylline; Phosphodiesterase Inhibitors; Ra | 2009 |
Anti-TNF therapy in alcoholic hepatitis.
Topics: Enzyme Inhibitors; Etanercept; Hepatitis, Alcoholic; Humans; Immunoglobulin G; Immunosuppressive Age | 2004 |
Steroids or cocktails for alcoholic hepatitis.
Topics: Adrenal Cortex Hormones; Antioxidants; Drug Therapy, Combination; Hepatitis, Alcoholic; Humans; Oxid | 2006 |